Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To demonstrate the efficacy of secukinumab 75 or 150 mg at Week 24 is superior to placebo in patients with active PsA based on the proportion of patients achieving an ACR20 response.
Critère d'inclusion
- Psoriatic Arthritis